Preclinical Development Of ROR1 Peptide Based Vaccine With Activity Against Chronic Lymphocytic Leukemia In ROR1 Transgenic Mice
Yu J, Cui B, Widhopf G et al.
Key Points:
Authors designed several different peptides, corresponding to distinct epitopes of ROR1.
Peptides conjugated with keyhole-limpet hemocyanin (KLH) to generate a peptide-KLH vaccine.
Vaccine (R22-KLH) induced high-titer anti-ROR1 antibody specific for ROR1-expressing cells.
Implications:
- Immunization with R22-KLH can induce high-titer anti-ROR1 antisera.
View the original abstract on the ASH website.
